Equities research analysts expect Recro Pharma Inc (NASDAQ:REPH) to post $24.06 million in sales for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Recro Pharma’s earnings, with estimates ranging from $22.70 million to $26.32 million. Recro Pharma posted sales of $21.74 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 10.7%. The firm is expected to announce its next quarterly earnings report on Tuesday, August 6th.
According to Zacks, analysts expect that Recro Pharma will report full-year sales of $91.91 million for the current financial year, with estimates ranging from $86.60 million to $100.95 million. For the next financial year, analysts forecast that the firm will post sales of $96.96 million, with estimates ranging from $87.60 million to $106.00 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Recro Pharma.
Recro Pharma (NASDAQ:REPH) last issued its quarterly earnings results on Friday, May 10th. The specialty pharmaceutical company reported ($0.10) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.79) by $0.69. Recro Pharma had a negative net margin of 83.56% and a negative return on equity of 654.93%. The company had revenue of $25.07 million during the quarter, compared to the consensus estimate of $20.51 million.
Shares of Recro Pharma stock traded up $0.04 on Thursday, reaching $8.99. 254,532 shares of the stock were exchanged, compared to its average volume of 264,125. Recro Pharma has a one year low of $4.78 and a one year high of $13.05. The company has a current ratio of 3.56, a quick ratio of 2.08 and a debt-to-equity ratio of 4.04. The company has a market cap of $199.41 million, a PE ratio of -3.61 and a beta of -0.13.
In related news, CEO Geraldine Henwood sold 144,806 shares of the stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $8.89, for a total value of $1,287,325.34. Following the completion of the transaction, the chief executive officer now owns 342,947 shares of the company’s stock, valued at approximately $3,048,798.83. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 20.10% of the stock is owned by corporate insiders.
A number of large investors have recently modified their holdings of REPH. Renaissance Technologies LLC boosted its stake in Recro Pharma by 26.0% during the 3rd quarter. Renaissance Technologies LLC now owns 480,500 shares of the specialty pharmaceutical company’s stock valued at $3,416,000 after purchasing an additional 99,200 shares in the last quarter. Oppenheimer & Co. Inc. boosted its stake in Recro Pharma by 5.5% during the 4th quarter. Oppenheimer & Co. Inc. now owns 32,313 shares of the specialty pharmaceutical company’s stock valued at $229,000 after purchasing an additional 1,683 shares in the last quarter. Rhumbline Advisers boosted its stake in Recro Pharma by 47.8% during the 4th quarter. Rhumbline Advisers now owns 23,753 shares of the specialty pharmaceutical company’s stock valued at $169,000 after purchasing an additional 7,679 shares in the last quarter. Essex Investment Management Co. LLC boosted its stake in Recro Pharma by 1.9% during the 4th quarter. Essex Investment Management Co. LLC now owns 257,707 shares of the specialty pharmaceutical company’s stock valued at $1,830,000 after purchasing an additional 4,833 shares in the last quarter. Finally, Monarch Partners Asset Management LLC boosted its stake in Recro Pharma by 57.4% during the 4th quarter. Monarch Partners Asset Management LLC now owns 55,857 shares of the specialty pharmaceutical company’s stock valued at $397,000 after purchasing an additional 20,367 shares in the last quarter. 56.12% of the stock is owned by institutional investors and hedge funds.
About Recro Pharma
Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
Read More: What is a trade deficit?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.